Objective To develop a polydimethylsiloxane (PDMS) microfluidic chip-based 18F microreactor for the preparation of 18F-labeled probes.Methods The 18F microreactor was composed of PDMS microfluidic chip and customized glass microvessel integrating with stainless capillary tube (D 0.6 mm) as heater/cooler.PDMS chips were fabricated by silk-screen printing technology,a traditional and easily accessible process.18F-FDG and 18F-fluoroacetate(FAC) were synthesized using the 18F microreactor.TLC was applied to measure the 18F-labeling yield and the radiochemical purity of 18F-FDG and 18F-FAC.Results The size of PDMS chip was 40.0 mm (l)×30.0 mm (w)×6.0 mm(h) and the liquid/gas inside channel was 0.3 mm (w)×50.0 μm (h).The customized glass microvessel was about 4.0 mm (D) ×30.0 mm (h) with 200 μl of reaction volume.The capillary tube which wrapped around the microvessel functioned as a heater when electric current was provided,while as a cooler when compressed air went through.The integrated 18F microreactor with a total size of 40.0 mm (l) ×30.0 mm (w) ×15.0 mm (h) was successfully used to prepare 18F-FDG and 18F-FAC,whose radiochemical purity were both higher than 96％ and 18F-labeling yield was 92.5％ and 90.0％ respectively in the first fluorination step.Conclusions A PDMS microfluidic chip-based 18F microreactor is developed and successfully applied to prepare 18F-FDG and 18F-FAC.It has the dual advantages of both microfluidc chip and traditional synthesis module and features of high integration,small total size and low consumption of labeling precursor.

Objective To explore the value of FDG PET-CT in the diagnosis of neurolymphomatosis (NL). Methods The clinical manifestation and FDG PET/CT imaging results in a patient with diffuse large B cell lymphoma accompanying peripheral neuropathy which was confirmed by pathological examination, were introduced. The images as shown by PET/CT were compared with the findings of traditional imaging including MRI and CT. Relevant literature was reviewed. Results A 38-year female patient complaining of left chest-back pain for 2 months came to hospital for treatment. An enhanced MRI of thoracic vertebrae showed osseous destruction on the left side of 4th thoracic vertebra and left posterior segment of 5th rib, and it was primarily diagnosed as a tumor. FDG PET/CT revealed a massively increased radioactive uptake in intervertebral foramen of left 4th, 5th thoracic vertebrae. The lesion was shown as an increase in uptake of radio-active substance along the left 5th intercostal nerve in the form of bundle or threads. A round-like nodule with increased radioactive uptake was observed in the left parasternal 2nd intercostal space. A CT-guided percutaneous needle biopsy of the nodule revealed a diffuse large B-cell lymphoma (A type). The lesion was shown to involve 4th, 5th thoracic vertebrae and left 5th intercostal nerve. It was diagnosed as NL. Repeated FDG PET imaging after chemotherapy showed normal radioactive distribution in the site of primary lesion area. Conclusions PET/CT is effective and sensitive in the diagnosis of NL, especially in patient with a history of malignant hematologic disease with clinical symptoms concerning peripheral nerve, accompanied by negative results with other examinations. Comparing with MRI, PET/CT can reveal involvement of peripheral nerve earlier, better reflect the degree of pathological condition, and reveal the number of nerves involved, as well as size and morphology of the lesion. It can reveal the active lesions of NL, and provide the target for needle biopsy.

Objective: To exolpre the feasibility to transform the metabolic process of active constituents of Chinese herbal medicine in vivo into images by PET/CT and to make quantitative analysis. Methods: The l-stepholidine was used as study object, and chemical synthesis of 11C-L-SPD was performed in hot room. PET/CT scan was performed in different time, 5, 15, 30, 45, 60, and 90 min after injecting 11C-L-SPD by vail in rats, and the information of brain, heart, lung, liver, kidney, intestine, and bladder was transferred to the Workststion. The distribution volume ratios (DVR) of the above tissues were obtained. Results: 11C-L-SPD was keeping in a relative higher level in liver and kidney at 5 min. metabolism through the liver, kidney was the main eccrisis organ. The distribution of 11C-L-SPD in liver, kidney, intestine, and bladder was (1.37 ± 0.42)%, (1.10 ± 0.19)%, (0.89 ± 0.18)%, and (0.97 ± 0.111)% respectively at 5 min and was (0.65 ± 0.11)%, (0.54 ± 0.05)%, (5.49 ± 1.44)%, and (9.86 ± 1.88)% respectively at 90 min. Conclusion: PET/CT imaging could observe the distribution and metabolism of 11C-L-SPD dynamically and directly. It could be used in the research of other Chinese medicines.

Benign metastasizing leiomyoma (BML) often occurs in women with a history of uterine leiomyoma at the childbearing age. At the same time, BML cases with multiple sites of metastatic lesions are extremely rare. A BML patient with multiple metastases of uterine leiomyoma in two lung and lumbar spine after surgery was admitted to Department of Spinal Surgery, Second Xiangya Hospital, Central South University in September 2017. Positron emission tomography/computed tomography (PET/CT) can perform a whole body examination for BML patients, which can find metastases in many parts of the body such as lung, abdominal cavity, pelvic cavity and spine. The PET/CT results are helpful to a comprehensive diagnosis. The imaging and clinical features of BML are now explored in combination with the characteristics of the case and relevant literature reports.
Female ; Humans ; Leiomyoma ; Lumbar Vertebrae ; Lung Neoplasms ; Positron Emission Tomography Computed Tomography ; Uterine Neoplasms

Objective: To investigate the value of statistical parametric mapping (SPM) analysis of ¹⁸F-fluorodeoxyglucose (FDG) PET imaging in the differential diagnosis of Parkinsonism in single-case level. Methods: SPM software was used to retrospectively analyze the ¹⁸F-FDG PET images of 160 patients (104 males, 56 females, age: 30-82 years) who were suspected with Parkinsonism at baseline and were clinical confirmed by follow-up from April 2010 to December 2017. ¹⁸F-FDG PET images of patients was compared with those of age-matched healthy controls in single-case level using two-sample t test in SPM software to obtain the imaging diagnosis. By comparing imaging diagnosis with the final clinical diagnosis, the diagnostic accuracy of SPM in the overall cohort as well as the early subcohort (duration of disease less than 2 years (56 males, 22 females, age: 50-82 years)) were calculated respectively. Results: Among 160 patients with Parkinsonism, 146(91.2%) had the same ¹⁸F-FDG PET diagnosis as their final clinical diagnosis. The diagnostic sensitivity for Parkinson′s disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and cortical basal ganglia degeneration (CBD) were 93.5%(86/92), 92.3%(24/26), 84.0%(21/25) and 15/17, respectively. The specificity were 95.6%(65/68), 95.5%(128/134), 96.3%(130/135) and 100%(143/143), respectively. In the early subcohort, the analysis also achieved similar differential diagnosis effectiveness(92.3%). Conclusion The single-case ¹⁸F-FDG PET imaging SPM analysis can be helpful in the early differential diagnosis of Parkinsonism effectively.

【Objective】 To analyze the correlation of whole body tumor burden of ¹⁸F-prostate specific membrane antigen positron emission computed tomography （¹⁸F-PSMA PET/CT） with prostate specific antigen （PSA） and Gleason score so as to evaluate the value of ¹⁸F-PSMA PET/CT whole body tumor burden for predicting serum PSA progression in prostate cancer. 【Methods】 We retrospectively recruited 213 patients with prostate cancer who underwent ¹⁸F-PSMA PET/CT scanning from March 2019 to April 2021. The serum PSA and Gleason score were collected. Whole body tumor burden was measured by a semi-automatic method. The correlation of tumor burden with serum PSA and Gleason score was analyzed. After radical prostatectomy， the patients were divided into groups according to negative or positive ¹⁸F-PSMA PET/CT. PSA differences between groups were compared， and the receiver operating characteristic curve （ROC） of the subjects was drawn so as to obtain the threshold value of PSA to predict the positive rate of ¹⁸F-PSMA PET/CT. The patients were followed up for PSA after radical surgery， divided into groups according to the progress of PSA， and the differences in tumor burden between groups were compared. 【Results】 In Gleason score ≤7， =8， and ≥9 groups， whole body tumor burden was correlated with PSA in each group （P=0.001）， and tumor burden significantly differed between the groups （P<0.001）. In initial diagnosis and treatment group， biochemical recurrence group， and medication group， the correlation between tumor burden and PSA was statistically significant （P=0.001）. The Gleason score of primary prostate lesion was significantly correlated with systemic tumor burden （P<0.001）. The area under ROC curve of PSA predicting the positive rate of ¹⁸F-PSMA PET/CT after radical prostatectomy was 0.821； when PSA>0.577 ng/mL， the sensitivity and the specificity were 66.7% and 96.8%， respectively. The mean whole body tumor burden in ¹⁸F-PSMA PET/CT positive patients with PSA progression was higher than that in patients without PSA progression. 【Conclusion】 The whole body tumor burden of ¹⁸F-PSMA PET/CT is significantly correlated with PSA， which is helpful in predicting the serum PSA progression in prostate cancer. PSA can predict the positive rate of ¹⁸F-PSMA PET/CT to a certain extent. At the same time， PSA can also predict positive results of ¹⁸F-PSMA PET/CT to a certain extent， and guide clinical rational selection of this examination.

In the Philippines, prostate cancer is the third most common malignancy among men. Over time, it tends to recur and/or progress to metastatic castration-resistant prostate cancer, wherein conventional therapies no longer work. Taking advantage of the high expression of prostate-specific membrane antigen (PSMA) on prostate cancer cells, 68GA- and 177 Lu-PSMA theranostics provides a targeted approach to imaging and therapy. With it's availabity in our country, patients now have an appealing and accessible treatment option. In this paper, we present five cases of metastatic castration-resistant prostate cancer, who have undergone 68Ga-PSMA PET/CT scans and 177Lu-PSMA radioligand therapies in the Philippines, to showcase the usefulness of theranostics in the local setting.
Positron Emission Tomography Computed Tomography ; Precision Medicine ; Prostatic Neoplasms ; Philippines

A 43-year-old female with a surgically unresectable and non-secretory mediastinal small cell neuroendocrine carcinoma waws previously given the protein kinase inhibitor Everolimus with intolerable nausea and fatigue. High somatostatin receptor expression of the known tumor was seen on 68Ga-DOTATATE PET/CT scan. She was then given 6.4 GBq of 177 Lu-DOTATATE with no adverse events. A follow-up 68Ga-DOTATATE PET/CT scan three months post-treatment showerd stable DOTATATE affinity with no evidence of metastasis. this case presents an overview of peptide receptor radionuclide therapy (PRRT), especially for multidisciplinary teams in the Philippines, as 68Ga and 177 Lu theranostics is introduced in the country.
Precision Medicine ; Philippines ; Carcinoma, Neuroendocrine

No abstract available.
Fluorodeoxyglucose F18 ; Humans ; Lymphoid Tissue ; Lymphoma

No abstract available.
Colon ; Fluorodeoxyglucose F18 ; Ulcer